Efficacy and safety of a new streptokinase regimen with enoxaparin in acute myocardial infarction

Journal of Thrombosis and Thrombolysis

Volumn 15, Issue 3, 2003, Pages 171-179

  Tatu Chitoiu, Gabriel ^a   Teodorescu, Cristina ^a   Dan, Monica ^a   Capraru, Petre ^a   Guran, Manuela ^a   Istratescu, Oana ^a   Tatu Chitoiu, Alexandrina ^a   Bumbu, Aurelia ^b   Dorobantu, Maria ^a  

^a Clinical Emergency Hospital   (Romania)

^b VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

Author keywords

Acute myocardial infarction; Coronary reperfusion; Enoxaparin; Streptokinase; Thrombolysis; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENOXAPARIN; FIBRINOLYTIC AGENT; HEMOGLOBIN; HEPARIN; METOPROLOL; NITRATE; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD TRANSFUSION; BODY WEIGHT; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY REPERFUSION; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; GINGIVA BLEEDING; HEMATOMA; HUMAN; HYPOTENSION; INCIDENCE; INTRAOCULAR HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHYSICIAN; PREDICTION; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; STROKE; THORAX PAIN;

AGED; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEMALE; HEPARIN; HUMANS; HYPOTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; STREPTOKINASE; SURVIVAL RATE;

EID: 1142291657     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:THRO.0000011372.26594.01     Document Type: Article

References (54)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.
3. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
4. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-770.
5. The GUSTO investigators. An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
6. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
7. Baigent C, Collins R. ISIS-2: 4-year mortality follow-up of 17,187 patients after fibrinolytic and antiplatelet therapy in suspected acute myocardial infarction. Circulation 1993;8:I-291.
8. International Resuscitation Guidelines 2000 - A Consensus on Science. Resuscitation 2000;46:1-447.
9. Smalling R, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. The RAPID Investigators. Circulation 1995;91:2725-2732.
10. Bode C, Smalling RW, Berg G, et al. Randomised comparison of coronary thrombolysis achieved with double bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissie plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. Circulation 1996;94:891-898.
11. International Joint Efficacy Comparison of Thrombolytics. Randomised double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet 1995;346:329-336.
12. Global Use of Strategies to Open Occluded Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-1123.
13. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Single-bolis tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. Lancet 1999;354:716-722.
14. In TIME-II Investigators. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs. accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000;21(24):2005-2013.
15. Den Heijer P, Vermeer F, Ambrosioni E, et al. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: A double-blind, randomized angiographic trial of lanoteplase versus alteplase. Circulation 1998;98(20):2117-2125.
16. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet 2001;357:1905-1914.
17. Tebbe U, Michels R, Adgey J, et al. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: The COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators. J Am Coll Cardiol 1998;31:487-493.
18. Ganz W, Geft I, Shah PK, et al. Intravenous streptokinase in evolving myocardial infarction. Am J Cardiol 1984;53:1209-1216.
19. Lew AS, Laramee P, Cercek B, Rodriguez L, Shah PK, Ganz W. The effects of the rate of intravenous infusion of streptokinase and the duration of symptoms on the time interval to reperfusion in patients with acute myocardial infarction. Circulation 1985;72:1053-1058.
20. Six AJ, Louwerenburg HW, Braams R, et al. A double-blind randomized multicenter dose-ranging trial of intravenous streptokinase in acute myocardial infarction. Am J Cardiol 1990;65:119-123.
21. Deutsche E. Endogenous and exogenous thrombolysis. Thrombosis et Diathesis Haemorrhagica 1971;(Suppl 47):145.
22. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-318.
23. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.
24. Antman EM, Cohen M, McCabe C, Goodman SG, Murphy SA, Braunwald E. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year, follow-up of TIMI 11B and ESSENCE. Eur Heart J 2002;23:308-314.
25. Klein W. Low molecular weight heparin in the initial and prolonged treatment of unstable coronary artery disease: The fragmin in unstable coronary heart disease study (FRIC). Eur Heart J 1996;17:306.
26. Antman EM. The search for replacements for unfractionated heparin. Circulation 2001;103:2310-2314.
27. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S.
28. Montalescot G, Gollet JP, Lison L, et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000;36:110-114.
29. Lewis BS, Ganz W, Laramee P, et al. Usefulness of a rapid initial increase in plasma creatine kinase activity as a marker of reperfusion during thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1988;62:20-24.
30. Hogg KJ , Hornung RS, Howie CA, Hockins N, Dunn FG, Hillis WS. Electrocardiographic prediction of coronary artery patency after thrombolytic treatment in acute myocardial infarction: Use of the ST segment and non-invasive marker. Br Heart J 1988;60:275-280.
31. Saran RK, Been M, Furniss SS, Hawkins T, Reid DS. Reduction in ST segment elevation after thrombolysis predicts either coronary reperfusion or preservation of left ventricular function. Br Heart J 1990; 64:113-117.
32. Hohnloser SH, Zabel M, Kasper W, Meinertz T, Just H. Assessment of coronary artery patency after thrombolytic therapy: Accurate prediction utilizing the combined analysis of three noninvasive markers. J Am Coll Cardiol 1991;18:44-49.
33. Shah PK, Cercek B, Lew AS, Ganz W. Angiographic validation of bedside markers of reperfusion. J Am Coll Cardiol 1993;21:55-61.
34. Mauri F, Maggioni AP, Franzosi MG, et al. A simple electrocardiographic predictor of the outcome of patients with acute myocardial infarction treated with a thrombolytic agent. A Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2)-Derived Analysis. J Am Coll Cardiol 1994;24:600-607.
35. Klootwijk P, Langer A, Meij S, et al. Non-invasive prediction of reperfusion and coronary artery patency by continous ST segment monitoring in the GUSTO-I trial. Eur Heart J 1996;17:689-698.
36. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613.
37. Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998;98:2805-2814.
38. White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: The HERO-2 randomised trial. Lancet 2001;358:1855-1863.
39. Ridker PM, O'Donnell C, Marder VJ, Hennekens CH. Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann Intern Med 1993;119:530-532.
40. Sleight P. Thrombolysis after GUSTO: A European perspective. Journal of Myocardial Ischemia 1993;5(8):25.
41. Ridker PM, O'Donnell C, Marder VJ, Hennekens CH. More on the GUSTO Trial. Ann Intern Med 1994;121:818.
42. Vorcheimer DA, Baruch L, Thomson TD, et al. North American vs. Non-North American streptokinase use in GUSTO-I: Impact of protocol deviation on mortality benefit of tPA. Circulation 1997;96:I-535.
43. Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med 1997;337:1124-1130.
44. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.
45. Mehta SR, Eikelboom JW, Yusuf S. Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: A meta-analysis. Lancet 2000;356:449-454.
46. Anschelevich M, Anschelevich I, Kochkaryov F. Safety of a new accelerated streptokinase regimen in acute myocardial infarction. Eur Heart J 1996;17(Abstract suppl):203.
47. Tatu-Chitoui G, Teodorescu C, Fluerasu A, et al. Accelerated streptokinase - A new thrombolytic regimen in acute myocardial infarction. Rom J Intern Med 1998;36:183-196.
48. Tatu-Chitoui G, Orha I, Teodorescu C, Fluerasu A, Serban L, Bumbu A. Rapid infusion of streptokinase standard dose in acute myocardial infarction is followed by a higher rate of coronary reperfusion than standard protocol. Rom J Intern Med 1997;35:47-54.
49. Esteves FP, Esteves PJ, Passos LC, et al. Coronary patency 90 minutes after intravenous (750,000 U, in 15 min) streptokinase in acute myocardial infarction - TROMBA study. Eur Heart J 1996;17(Abstract suppl):203.
50. Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: Second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001;104:648-652.
51. Simoons M, Krzeminska-Pakula M, Alonso A, et al. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur Heart J 2002;23:1282-1290.
52. Baird SH, Menown IB, Mcbride SJ, Trouton TG, Wilson C. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J 2002;23:627-632.
53. Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002;105:1642-1649.
54. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999;34:890-911 (Available at www.acc.org. Accessed on 18 October 2002).